

Partner Organization Report

Partner Organization:	AHCTA
Committee Name (if applicable):	N.A.
ISCT Representative(s):	Karin Hoogendoorn
Role of ISCT Representative:	Represents the ISCT Europe Region within AHCTA
Last Committee Report Submitted on:	
Date of Upcoming Board of Directors Meeting for Submission:	June 20, 2018

1. How often has this committee met during the last 12 months?

January 2017- May 2018: 6 meetings; 2 cancelled

04Jan2017; 01Feb2017; 05APR2017; 14Jun2017; 06Dec2017; 04/Apr2018

Cancelled: 02Aug2017; 04Oct2017.

2. What was accomplished during the meeting(s)? (To answer this question, you may attach conference call reports or meeting minutes.)

- Preparation for January 2017 in Riyadh workshop (tissues& cells and transplantation standards, accreditation)

- Transfer AHCTA website to WBMT; discussion on the new website: design, content, what to find where: <https://www.wbmt.org/ahcta/home/>

- Discussed standards for transplantation on labelling and coding; cell processing; cell collection – those are not standards but used to align on terminology and identify gaps/differences among tissues & cells organizations (see link to documents)

<https://www.wbmt.org/ahcta/documents/>

- Costs of stem cell transplantation

- Discuss global transplantation survey

- 2017 WBMT (worldwide network for blood and bone marrow transplantation) report:

https://www.wbmt.org/fileadmin/pdf/01_General/2017_WBMT_Progress_Report.pdf

3. What are the key goals and initiatives for the next 6 months to 1 year?

- Preparation for the 5th WHO/WBMT workshop in Beijing, Sep2018.

https://www.wbmt.org/fileadmin/pdf/Beijing_2018/WBMT_workshop_announcement_Beijing_2.pdf

- Further harmonization and development of global and regional standards

4. Are there any activities within this time period that ISCT should be aware of or take part in? Specifically, are there activities that any ISCT Committees can comment on?

- Further harmonization and development of global and regional standards- a lot in common with ISCT activities: track & traceability, storage, transport.

5. Additional comments or feedback:

- Maybe we can organize a workshop/ meeting related to standards/guidance, mapping this out (globally or regionally), share initiatives and cross fertilize among groups and organizations. A lot is initiated within ISCT, but also AHCTA, ARM, EBE/EFPIA, Europabio, regulatory bodies, ISO in conjunction with IABS/WHO, NIBSC, etc, etc.... There is a lot to share and we should, where possible and applicable, try to prevent from wheels to be reinvented.
- Capacity building: more and more biotech companies, SMEs, big pharma, but also academic centers are involved in ATMP and cell therapy development. The education, both at BSc, MSc, MD, PharmD, PhD and other levels is lacking. There are and will be huge shortcomings in the very near future of experienced and trained personnel. Maybe ISCT could also play a more dominant role and take this up....a huge network of experienced people.